Spherix Global Insights

May 12, 2016

Pfizer’s Xeljanz Benefits from Biologic Switching in Rheumatoid Arthritis, According to Spherix Global Insights

Download Report Overview

Analysis of RA patients switched from one biologic/JAK to another brand in the past three months indicate that Xeljanz has the greatest net gains when switching occurs.

May 12, 2016, Zug, Switzerland – Spherix Global Insights reveals that Xeljanz is carving a niche as a popular switch-to-agent in second and later lines of biologic/JAK therapy for the treatment of rheumatoid arthritis (RA).  Specifically, Xeljanz accounts for 16% of patients recently switched from a biologic in the past three months, second only to AbbVie’s Humira, which captures 22% of the recently switched population.

With regard to overall net changes in patient share from recent switches, Xeljanz benefits most with an overall 13% net increase, followed by Roche’s Actemra which captures a 7% net gain in share.  Conversely, Amgen’s Enbrel and Humira experience the greatest losses during switching, with overall net declines of 15% and 10%, respectively.

Additionally, treating rheumatologists report that Xeljanz, Actemra and Bristol-Myers Squibb’s Orencia stand to gain the most from anticipated future switching when patients are unresponsive to their current biologic/JAK.

According to Robbie McCarthy at Spherix Global Insights, “Xeljanz and the alternate MOA biologics are popular switch options for the treatment of RA.  The future of RA switch dynamics will become increasingly competitive when other JAK and IL-6 inhibitors, such as Eli Lilly/Incyte’s Baricitinib and Regeneron/Sanofi’s Sarilumab, are approved and available for use.”

The most common reasons behind the selection of switch-to biologic/JAK brands are different mechanism of action, different dosing interval, and different dosing delivery, all three of which are key distinguishing attributes of Xeljanz.  However, insurance mandates were the primary reason behind switch-to brand selection in 12% of the recently switched audited patients. As expected, the established TNF-inhibitors benefit most from their preferred status among insurance providers,

while it is extremely rare for insurance providers to mandate treatment with Xeljanz, Orencia IV, or Actemra SC.

Further biologic and Xeljanz switching dynamics are covered in depth in RealWorld Dynamix: Biologic and Xeljanz Switching in Rheumatoid Arthritis, which includes data from 200 surveyed U.S. rheumatologists and analysis of nearly 1000 de-identified RA patient records.

About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets.  Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact: 
Dan Cassidy, Business Development
Telephone:  800-661.0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com